Beigene Ltd (NASDAQ:BGNE)

380.02
Delayed Data
As of Sep 24
 -5.40 / -1.40%
Today’s Change
219.20
Today|||52-Week Range
426.56
+47.07%
Year-to-Date
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
Sep 21 / GuruFocus News - Paid Partner Content
3 Top Chinese Stocks to Watch in September
Sep 15 / MotleyFool.com - Paid Partner Content
Why BeiGene's Shares Jumped on Friday
Sep 17 / MotleyFool.com - Paid Partner Content
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
Sep 13 / Zacks.com - Paid Partner Content
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
Sep 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close385.42
Today’s open378.87
Day’s range372.55 - 381.11
Volume8,478
Average volume (3 months)297,488
Market cap$37.5B
Data as of 4:14pm ET, 09/24/2021

Growth & Valuation

Earnings growth (last year)-21.11%
Earnings growth (this year)+37.87%
Earnings growth (next 5 years)+37.00%
Revenue growth (last year)-27.87%
P/E ratioNM
Price/Sales69.83
Price/Book9.54

Competitors

 Today’s
change
Today’s
% change
TEVATeva Pharmaceutical-0.11-1.16%
BBIOBridgeBio Pharma Inc-1.35-2.71%
----
IMMBImmunotech Laborator...0.000.00%
Data as of 4:15pm ET, 09/24/2021

Financials

Next reporting dateNovember 11, 2021
EPS forecast (this quarter)-$4.58
Annual revenue (last year)$308.9M
Annual profit (last year)-$1.6B
Net profit margin-517.01%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Beijing, Beijing

Forecasts